A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D)

INTRODUCTION: Immune activation has been reported in the mucosa of IBS patients with diarrhoea (IBS-D), and some small studies have suggested that mesalazine may reduce symptoms. We performed a double-blind, randomised placebo-controlled trial of 2 g mesalazine twice daily versus placebo for 3 month...

Descripción completa

Detalles Bibliográficos
Autores principales: Lam, Ching, Tan, Wei, Leighton, Matthew, Hastings, Margaret, Lingaya, Melanie, Falcone, Yirga, Zhou, Xiaoying, Xu, Luting, Whorwell, Peter, Walls, Andrew F, Zaitoun, Abed, Montgomery, Alan, Spiller, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Neurogastroenterology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717357/
https://www.ncbi.nlm.nih.gov/pubmed/25765462
http://dx.doi.org/10.1136/gutjnl-2015-309122

Ejemplares similares

Ejemplares similares